[go: up one dir, main page]

WO2018142363A1 - Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables - Google Patents

Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables Download PDF

Info

Publication number
WO2018142363A1
WO2018142363A1 PCT/IB2018/050709 IB2018050709W WO2018142363A1 WO 2018142363 A1 WO2018142363 A1 WO 2018142363A1 IB 2018050709 W IB2018050709 W IB 2018050709W WO 2018142363 A1 WO2018142363 A1 WO 2018142363A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
glp
pharmaceutical preparation
injection
sterile
Prior art date
Application number
PCT/IB2018/050709
Other languages
English (en)
Inventor
Mailatur Sivaraman Mohan
Hiren Patel
Bhaveshkumar VALLABHBHAI PATEL
Raghu KANNEKANTI
Paramesh CHAKALI
Kantu BABUJI
Original Assignee
Orbicular Pharmaceutical Technologies Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbicular Pharmaceutical Technologies Private Limited filed Critical Orbicular Pharmaceutical Technologies Private Limited
Publication of WO2018142363A1 publication Critical patent/WO2018142363A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a stable ready-to-use pharmaceutical preparation of GLP-2 analogue for parenteral administration, wherein the preparation comprises GLP-2 analogue or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients and the preparation are administered as multi-dose fixed dose and/ or single dose injections through self-administrable devices.
  • Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene. Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action. GLP-2 regulates gastric motility, gastric acid secretion, intestinal hexose transport, and increases the barrier function of the gut epithelium. GLP-2 significantly enhances the surface area of the mucosal epithelium via stimulation of crypt cell proliferation and inhibition of apoptosis in the enterocyte and crypt compartments. Teduglutide, is a protease-resistant analog of GLP-2 for the potential treatment of
  • US7056886 patent publication disclose the h[Gly2]GLP-2 lyophilized formulation comprising in the reconstituted product: phosphate buffer in an amount necessary to maintain the pH of the reconstituted product pH of about 7.3 to about 7.4; about 0.5 to about 1% L-histidine; about 3% mannitol.
  • Teduglutide is commercially available as GATTEX ® (teduglutide [rDNA origin]), single use glass vial which is a lyophilized formulation available as 5mg/vial sterile, white lyophilized powder for reconstitution with 0.5mL Sterile water for Injection provided in a prefilled syringe.
  • GATTEX teduglutide [rDNA origin]
  • each vial of GATTEX contains 3.88 mg L-histidine, 15 mg mannitol, 0.644 mg monobasic sodium phosphate monohydrate, 3.434 mg dibasic sodium phosphate heptahydrate as excipients.
  • the lyophilized powder is reconstituted with 0.5 mL of sterile water for Injection, which is provided in a prefilled syringe.
  • Reconstitute each vial of GATTEX by slowly injecting 0.5 mL of preservative-free sterile water for Injection provided in the prefilled syringe. Allow the vial containing GATTEX and water to stand for approximately 30 seconds and then gently roll the vial between your palms for about 15 seconds. Do not shake the vial. Allow the mixed contents to stand for about 2 minutes. Inspect the vial for any undissolved powder. If undissolved powder is observed, gently roll the vial again until all material is dissolved. Do not shake the vial. If the product remains undissolved after the second attempt, do not use. It is for single-use only and discard any unused portion.
  • compositions are lyophilized and reconstituted before use, lyophilization of the drug is done to avoid the stability issues. Further the reconstituted compositions are not stable and must be used within 3 hours after reconstitution. It requires initial
  • the present invention relates to a stable, ready-to-use pharmaceutical preparation of GLP-2 analogue for parenteral administration, wherein the preparation comprises GLP-2 analogue or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients.
  • the invention also relates to a stable ready-to-use pharmaceutical preparation of GLP-2 analogue for parenteral administration in a multiple dose or a single dose injection device comprising a sterile solution in a reservoir, wherein the GLP-2 analogue is dissolved in a pharmaceutically acceptable vehicle, wherein said reservoir comprises multiple doses or single dose of said sterile solution; wherein the device is adapted to subcutaneously inject a single daily dose or deliver multiple doses, while the solution remains sterile.
  • the present invention relates to a stable, ready-to-use pharmaceutical preparation of GLP-2 analogue for parenteral administration, wherein the preparation comprises GLP-2 analogue or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients.
  • the present invention also comprises glepaglutide, a novel GLP-2 analogue with the potential to improve treatment of patients with short bowel syndrome.
  • the present invention shall comprise of glepaglutide as a GLP-2 analogue for the treatment of short bowel syndrome (SBS).
  • SBS short bowel syndrome
  • active ingredient refers to a substance that has a physiological effect when ingested or otherwise introduced into the body, in particular or a chemical substance used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well- being.
  • excipient or “pharmaceutically acceptable excipient” or “adjuvant” means a component of a pharmaceutical product that is not a pharmacologically active ingredient, such as diluent, bulking agent, carrier, acidifying agent, pH modifier, buffering agent, chelating agent, solvent, co- solvent, tonicity adjusting agent, antioxidant, preservative and the like added to a drug to increase or aid its effect.
  • excipients or adjuvants that are useful in preparing pharmaceutical compositions are generally safe, non- toxic, and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use.
  • the term includes one or more excipients or adjuvants.
  • composition is intended to encompass a combination including active ingredients and pharmaceutically acceptable excipients, as well as any product which results, directly or indirectly, from combination, complexation, or aggregation of any two or more of the
  • formulation or from dissociation of one or more of the ingredients, or from other types of reactions or interactions involving one or more of the ingredients.
  • formulation or "dosage form” or “composition” refers to finished pharmaceutical products that are suitable for administration, including, but not limited to, injections, etc.
  • Stability or “stable” as used herein includes both physical and chemical stability. Stability parameters include but not limited to potency, stable pH value and other physico-chemical parameters.
  • Self-administrable devices may include prefilled syringe, prefilled syringe with auto-injector, dual chamber prefilled syringe, dual chamber cartridge with pen injection device, dual chamber cartridge with auto-injector, cartridge with pen injection device and the like.
  • Carrier or “vehicle” or “solvent” as used herein refers to
  • pharmacologically inert materials that provide a more or less fluid matrix, suitable for topical drug administration.
  • Carriers and vehicles useful herein include any such materials known in the art, which are nontoxic and do not interact with other components of a pharmaceutical formulation or drug delivery system in a deleterious manner.
  • the formulations of the present invention are particularly suitable for parenteral administration.
  • Formulations suitable for parenteral dosage forms such as injectable like intravenous, intramuscular or subcutaneous, implants and the like.
  • Other parenteral ingredients used in the formulation are generally those commonly used and recognized by persons skilled in the art of parenteral formulations.
  • “Pharmaceutically-acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts, solvate, hydrate, esters and the like thereof.
  • Pharmaceutically-acceptable salt forms of compounds provided herein are synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • the pharmaceutical preparation includes different GLP-2 analogues such as teduglutide or its pharmaceutically acceptable salt and the like, GLP-2 analogues as disclosed in US 5994500 A, US 5789379 A, US 9125882 B2 and US 6184201 B1 , glepaglutide or its pharmaceutically acceptable salt and the like.
  • the pharmaceutical preparation further comprises of excipients such as tonicity adjusting agent, buffering agent, vehicle, carrier, pH modifiers, antioxidants, preservatives, chelating agents, bulking agents, diluents, surfactant, stabilizers and the like or mixtures thereof.
  • excipients such as tonicity adjusting agent, buffering agent, vehicle, carrier, pH modifiers, antioxidants, preservatives, chelating agents, bulking agents, diluents, surfactant, stabilizers and the like or mixtures thereof.
  • tonicity adjusting agent include but not limited to mannitol, sucrose, maltose, dextrose, trehalose, glycerin, sodium chloride, potassium chloride or mixtures thereof.
  • Tonicity adjusting agents decrease the haemolysis of blood cells and reduce pain and irritation at the injection site.
  • the amount of tonicity adjusting agent used in the said preparation is adjusted to obtain osmolality of the said preparation in the range of 290 to 330 mOsm/kg.
  • buffering agent examples include but not limited to acetate, citrate, tartrate, phosphate, benzoate, lactate, gluconate, bicarbonate, organic amines, its salts, hydrates, solvates, or any mixtures thereof.
  • vehicle or carriers examples include but not limited to water for injection, hydroalcoholic solvents like, propylene glycol, polyethylene glycol, ethanol, glycerol and mixtures thereof.
  • antioxidants include but not limited to monothioglycerol, L- cysteine, thioglycolic acid, sodium metabisulfite, ascorbic acid, sodium formaldehyde sulfoxylate, sodium bisulfate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA), phenylmercuric nitrate, thiomersal,
  • benzalkonium chloride benzethonium chloride, phenol, cresol or chlorobutanol.
  • preservatives include but not limited to benzyl alcohol, m- cresol, phenol, methyl parabens, propylparaben, butylparaben, chlorbutanol, thiomersal, phenylmercuric salts, or mixtures thereof.
  • the sterile solution of the present invention comprises preservative in amounts sufficient to maintain sterility of the solution in the multiple dose pen injection device, throughout the shelf life of the product, which may be exposed to repeated multiple injections. This is because it is possible that the antimicrobial preservative concentration in a given preparation may decrease during the product's shelf life.
  • chelating agents include but not limited to ethylene diamine tetraacetic acid (EDTA) and acceptable salts thereof, citric acid, sodium citrate, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and acceptable salts thereof, and 8-Amino-2-[(2-amino-5-methylphenoxy) methyl]-6- methoxyquinoline-N,N,N',N'-tetraacetic acid, tetrapotassium salt (QUIN-2) and acceptable salts thereof and the like or mixtures thereof.
  • EDTA ethylene diamine tetraacetic acid
  • EGTA ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid
  • QUIN-2 8-Amino-2-[(2-amino-5-methylphenoxy) methyl]-6- methoxyquinoline
  • stabilizers include but not limited to polyols, amino acids, surfactants, poloxamer and its co-polymers; polyols include but not limited to propylene glycol, polyethylene glycol, polypropylene glycol and the like or mixtures thereof; amino acids include but not limited to aspartic acid, glutamic acid, glycine, arginine, lysine, L-histidine and the like or mixtures thereof;
  • surfactants include but not limited to polysorbate-20, polysorbate-80, and the like or mixtures thereof.
  • the pharmaceutical preparation wherein the concentration of dose is in the range from about 2 mg/mL to about 200 mg/ml of the preparation.
  • the pharmaceutical preparation wherein the device provides fixed dose as a multi dose pen injection device or a single dose injection device to give a fixed desired dose, as specified from about 2 mg/mL to about 200 mg/ml of the preparation.
  • the pharmaceutical preparation wherein the device comprises of a reservoir comprising multiple doses of liquid injection or single dose quantity of injection to provide the desired dose.
  • pH of the preparation is between about 7 to about 8.5.
  • a multiple dose pen injection device or a single dose injection comprising a reservoir of a sterile solution comprising teduglutide, tonicity adjusting agents, buffering agent, vehicle or carrier, antioxidant, stabilizer, and optionally preservative, the device being adapted to provide a portion of the reservoir directly from the multiple dose pen injection device in a single subcutaneous injection, said portion comprising teduglutide in a pre-determined dose and the device further being adapted to provide multiple portions of the said solution while the reservoir remains sterile.
  • the present invention relates to self-administrable devices such as multiple dose pen injection device and/ or independently a single dose reusable auto- injector device which has the provision to mount the ready to use prefilled syringes or suitable sterile container and/or reconstituted product filled in the prefilled syringe or suitable sterile containers to provide different fixed doses, comprising a sterile solution of teduglutide in a pharmaceutically acceptable vehicle.
  • Reconstituted product refers to the lyophilized product upon
  • the sterile solution is present as reservoir; the device being adapted to subcutaneously inject a portion of the said reservoir as multiple dose pen injection or as a single daily dose of said solution while the reservoir remains sterile.
  • the sterile solution is presented as a multiple dose preparation that is, the sterile reservoir of the solution that can be used for delivering multiple doses or as a single dose through a reusable auto- injector comprising a sterile solution either filled in a prefilled syringe or suitable sterile container and/ or reconstituted product filled in the prefilled syringes or suitable sterile container.
  • the reservoir of the sterile solution is present in the multiple dose pen device or prefilled syringe or suitable sterile container and a portion of that reservoir or container is withdrawn for each administration.
  • the portion suitably contains a desired dose of teduglutide.
  • the sterile solution of the present invention is meant for single dose administration as well.
  • the sterile solution of the present invention optionally includes preservative in amounts sufficient to maintain sterility of the solution in the multiple dose pen injection device, throughout the shelf life of the product, which may be exposed to repeated, daily multiple injections.
  • Suitable preservatives for the solution includes but are not limited to, benzyl alcohol, m-cresol, phenol, methyl parabens, propyl paraben, butyl paraben, chlorobutanol, thiomersal, phenyl mercuric salts, and the like.
  • benzyl alcohol when the solution contains benzyl alcohol as the preservative, it is present in an amount sufficient to maintain sterility of the solution in the multiple dose pen injection device, throughout the shelf life of the product, which may be exposed to repeated multiple injections.
  • the multiple dose pen injection device comprises a reservoir filled with a solution of teduglutide, comprising a suitable preservative.
  • the preservative containing solution is aseptically filtered (0.2-micron filter) and filled in pre-sterilized reservoir aseptically under sterile area.
  • the solution comprises teduglutide along with a preservative agent to keep the sterility maintained while being used multiple times throughout the shelf life of the product.
  • the pharmaceutically acceptable vehicle may comprise a buffer or tonicity adjusting agent.
  • the pH of the solution is suitably adjusted to a pH range of 2 to 9.
  • the pH may be adjusted using a suitable pH modifier.
  • a buffer system to maintain the pH range.
  • Suitable buffers include, but are not limited to acetate, citrate, tartrate, phosphate, benzoate, lactate, gluconate, bicarbonate, organic amines or any mixtures thereof and the like.
  • the sterile solution may optionally comprise other excipients known in the art to obtain a stable pharmaceutical preparation.
  • the preservative efficacy test is performed to evaluate the performance of a preservative.
  • Such tests are described in literatures, such as for eg. Pharmacopoeias.
  • the solution being suitable for multiple dosing, the PET may be performed.
  • the sterile solution of the present invention being a multi dose preparation, it needs to maintain sterility during its shelf life that is while being used.
  • the solution of the present invention in the multiple dose pen injection device was subjected to in-use stability testing.
  • the routine procedure provided by United States Food and Drug Administration (FDA), United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) are followed to evaluate the sterility.
  • the tests are PET (preservative Efficacy tests), sterility and BET (Bacterial Endotoxin Test).
  • An in-use shelf-life is intended to provide assurance of the appropriate quality of the product throughout its use, thereby ensuring the safety and efficacy of the product.
  • the in-use shelf-life specified depends on the product, in particular its physical, chemical and microbiological characteristics.
  • the in-use shelf-life is generally 28 days, however it may be less than this, for example if the active substance is prone to degradation following exposure to the atmosphere, or it may be longer than this, for example for a product which is very stable and which will not support the growth of micro-organisms (like some non-aqueous/oily injections). It is clear that during development of multi-dose sterile products it is necessary to carry out in-use studies to prove that a product remains physically and chemically stable and sterile during the in-use period.
  • the sterile solution of teduglutide can be prepared by the following process which involves:
  • suitable buffers amino acid, optionally surfactant, antioxidant, optionally preservative, are added to the above solution followed by the addition of active ingredient teduglutide and stir to dissolve followed by pH adjustment of the solution.
  • step (iii) solution is optionally lyophilized in a dual chamber prefilled syringe to obtain a lyophilized cake or powder and water for injection is filled in other chamber.
  • the above described process is carried out at controlled temperature and during the process the nitrogen purging is carried out at required steps.
  • each ml_ comprises of teduglutide, arginine, mannitol, optionally poloxamer, optionally phenol or m- cresol, monothioglycerol, monobasic and dibasic sodium phosphate buffers, water for injection, and nitrogen gas is purged.
  • each ml_ comprises of teduglutide, L-histidine, mannitol, optionally polysorbate 80, optionally phenol or m-cresol, monothioglycerol, monobasic and dibasic sodium phosphate buffers, water for injection and nitrogen gas is purged.
  • the proposed preparations are presented as a single dose or multiple doses to provide the required doses, wherein, single dose is provided as a dual chamber prefilled syringe comprising two chambers, one chamber comprising the commercially available composition in lyophilized form and other chamber comprises of sterile water for injection.
  • Other single dose preparation is provided as a ready to use composition in prefilled syringes, wherein, both the prefilled syringes are provided to fit into a re-usable auto-injector.
  • Multidose preparations are filled in cartridges to provide multiple doses of up to 28 doses through a pen injection device, after which the device shall get locked and cannot be used thereafter.
  • Each millilitre of the preparation comprises about 20 mg to about 50 mg of teduglutide with other excipients, which can be administered as a multiple dose.
  • Multi dose preparations are presented in the sterile reservoir of the solution that can be used for delivering multiple doses or through a pen injection device comprising a sterile solution either filled in a cartridge or suitable sterile
  • Fill volume of preparation for multiple dose includes from about 0.05 ml_ to about 4.0 ml_, for example between about 0.1 ml_ to about 3.5 ml_.
  • Single dose preparation comprises 2 mg to 5 mg of teduglutide and can be administered as a prefilled syringe comprising a dual chamber reservoir comprising lyophilized preparation in one chamber and water for injection in another chamber and reconstituted before administration.
  • single dose preparation shall also be administered as a ready to use composition comprised in a reusable auto- injector device.
  • Fill volume of preparation includes from about 0.05 ml_ to about 4.0 ml_, for example between about 0.1 ml_ to about 3.5 ml_.
  • predetermined fixed dose supplied as multi dose pen injection device which has the provision to mount the ready to use prefilled syringes or suitable container and/or reconstituted product filled in the prefilled syringe or suitable containers to provide fixed desired doses.
  • Another embodiment provides a multi dose pen injection device and a method for administering a single predetermined dose of a solution containing teduglutide.
  • the inventive device is having a reservoir containing a solution of teduglutide.
  • the elongate, compact shape of the pen delivery device facilitates the use of simple pull-push handling techniques and allows the patient to easily carry the device on his/her person.
  • the pen device is designed so that only a single predetermined dose is easily loaded by the patient using a pull-push technique of the device.
  • the designed pen device is easy-to-use for all multi dose fixed dose therapies and the handling of device is simple and intuitive.
  • Simple pull-push technique is easy to handle and ensures a high level of patient convenience, loading a partial dose is not possible to avoid dosing errors.
  • Suitable marking indicates whether the dose button needs to be pulled or pushed and the display is completely customizable.
  • the device indicates to the patient distinct and perceptible clicks to confirm whether the dose is loaded and also at the end of injection. Active last dose stop prevents the loading of a partial dose when the reservoir is nearly empty. Moreover, having only a single dose setting greatly reduces the possibility of a patient under dosing or overdosing himself or herself.
  • the dosing sleeve of the pen device is calibrated and visibly marked with a single priming position indicator and a single predetermined injectable dose position indicator.
  • This calibration and marking of the dose sleeve is a significant departure from existing pen delivery devices typically used for insulin, or human growth hormone delivery. Those existing devices are characterized in that they can deliver a great number of different dosages depending on where the patient or health care provider recommend dose.
  • the dose sleeve devices are marked and calibrated in International Units, having different possible
  • teduglutide typically requires only a single, predetermined, non-varying dose on a daily basis.
  • Another embodiment relates to auto-injector in a self-contained, reusable multi use, preset and prefilled device configured to present a dosing choice to an end-user and to deliver a dose associated with the choice made by the end-user.
  • the auto-injector is configured to be capable of delivering a single dose chosen from a plurality of different doses of a pharmaceutical composition or medicament.
  • the auto-injector is configured to be capable of delivering a single dose chosen from two different doses of a pharmaceutical composition or medicament.
  • the device is capable of delivering different preset doses.
  • the prefilled device may be a single chamber or a dual chamber, wherein single chamber may comprise of the ready to use preparation and a dual chamber may comprise of lyophilized composition in one chamber and diluent in other chamber.
  • the sterile solution filled prefilled syringe should be loaded into the reusable auto-injector device and ensure proper closure of the device to make ready for dosing. Before initiating next dose ensure the rigid needle shield should be removed or ejected form auto- injector device. After removing the needle shield the recorded dose is administered immediately.
  • the working principle of the disclosed auto- injector device is similar or advanced to the auto- injector available in the general art.
  • the auto-injector is thereby configured to administer to a patient a pharmaceutical composition stored in a medicament reservoir disposed within it.
  • the medicament reservoir cooperates with the dose selection component so that only the volume of pharmaceutical composition, at a given concentration corresponding to the selected dose is administered to the patient using the device.
  • the medicament reservoir is a suitable device such as prefilled syringe and the like thereof, incorporated into the auto-injector housing, either permanent or removable.
  • Selection of the dose is made by some form of manipulation of the injector such as by use of a button, slide, dial, shaking, audible/visible selection, or other input mechanism on the self-contained, single use, auto-injector.
  • the injection device is calibrated so that only the amount of medicament that corresponds to the end-user dosage selection is dispensed from the reservoir and administered to the patient.
  • the injection device is capable of accurately administering a full dose of a medicament or pharmaceutical preparation. Prior to administration or priming of the device may still be configured to be locked.
  • the self-contained, single selectable dose auto-injector can be manufactured by providing a single selectable dose injector which has a selector. The selector can be actuated to dispense a single time, one of two pre-determined volumes of a liquid containing an active agent useful for treating the required condition.
  • Another embodiment relates to a single dose injection which can be administered by reusable single dose auto-injector device by mounting a prefilled syringe.
  • Materials used for the preparation of prefilled syringe include but not limited to polypropylene, glass, plastics or polymers such as Cyclic olefin polymer (COP) or Cyclic olefin co-polymer (COC), polyethylene high density, polyethylene low density and the like or combinations thereof.
  • Further other components for the prefilled syringe include barrel, plunger stopper, tip cap, plunger rod, lubricant, needle, needle shield cover, lock adapter, tamper evident, finger grip extender or back stop may be made of the material available in general art.
  • a preset dose of a liquid drug includes two sleeve-like components releasably connected with each other so as to be aligned in axial direction.
  • One of the sleeve-like components is a holder for a dispensing mechanism and the other of the sleeve-like components is adapted to
  • the dispensing mechanism includes an axially movable plunger rod for actuating plunger of the reservoir.
  • the plunger rod has a radially projecting cam follower and the holder defines at least one axially extending slot having a predetermined length, wherein the cam follower is received by at least one slot, such that only a single dose can be dispensed from a reservoir by an axial movement of the plunger rod.
  • Another embodiment relates to a delivery pen that houses reservoir assembly containing reservoir that has the capability of holding about a 60day supply of daily doses of the pharmaceutical compositions described herein.
  • the pen has the capability of holding a 1 , 2, 3, 4, 5, 6, 7, or 8-weeks or more supply of daily doses of the pharmaceutical compositions described herein.
  • Such a device provides ease of use for self- administration of the pharmaceutical compositions described herein.
  • the sterile container can contain a liquid dosage of the pharmaceutical composition, which is reconstituted by the user prior to injection.
  • medication delivery reservoir may be cartridge, prefilled syringe or suitable sterile containers assemblies and the like for holding the liquid comprising the pharmaceutical preparation.
  • the reservoir containers were first pre sterilized by an appropriate sterilization process and then the solutions were filled aseptically under sterile area.
  • the material of construction of the reservoir containers can be either glass or plastic and the like. Depending upon the material, a suitable sterilization process can be adapted.
  • the present invention provides a method of
  • administration of teduglutide to a subject in need thereof comprising daily subcutaneous administration of solution of teduglutide to the subject, wherein the solution is administered directly from the multiple dose pen injection device.
  • This may be of particular importance in case of administration in children, where individualization for each child is necessary and the dose is based on mg/kg ratio of drug to body weight.
  • the multiple dose pen injection device of the present invention imparts fixed dose of the medicament as well as the
  • the device thus provides an accurate and convenient method of administration of teduglutide which is not available in the art.
  • the device is capable of offering the end-user a choice between a complete single dose or multi dose of the pharmaceutical preparation by using the auto- injector or multi dose pen injection device.
  • a single dose is a predetermined volume of liquid containing the active agent at a fixed concentration, corresponding to essentially the entire reservoir volume of the device.
  • the invention relates to the use of the GLP-2 analogues for treatment or prophylactic treatment of gastrointestinal disorders as well as stomach and intestinal-related disorders in a human or animal subject.
  • Gastrointestinal disorders include the disorders of the upper gastrointestinal tract of the oesophagus.
  • Stomach and intestinal-related disorders include ulcers of any aetiology (e.g. peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers related to infections or other pathogens), digestion disorders, malabsorptions, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), celiac sprue,
  • hypogammaglobulinemic sprue and chemotherapy and/or radiation therapy- induced mucositis and diarrhea.
  • the disclosed preparations may be used alone or in combination with other therapeutic agents such as an anti-osteoporosis agent, hormones such as peptide hormone, steroid hormone or a non-steroid hormone, a bisphosphonate compound, growth hormone secretagogue, selective estrogen receptor modulator, protease inhibitor, DPP IV antagonist or inhibitors and the like or any combinations thereof.
  • Example 1 Multidose preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne une préparation pharmaceutique stable d'analogue de GLP-2 prête à l'emploi par administration parentérale, cette préparation comprenant un analogue de GLP-2 ou son sel pharmaceutiquement acceptable et des excipients pharmaceutiquement acceptables. L'invention concerne en outre des injections à doses fixes multiples et/ou à dose unique de cette composition par l'intermédiaire de dispositifs auto-administrables.
PCT/IB2018/050709 2017-02-06 2018-02-05 Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables WO2018142363A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741004264 2017-02-06
IN201741004264 2017-02-06

Publications (1)

Publication Number Publication Date
WO2018142363A1 true WO2018142363A1 (fr) 2018-08-09

Family

ID=63039400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/050709 WO2018142363A1 (fr) 2017-02-06 2018-02-05 Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables

Country Status (1)

Country Link
WO (1) WO2018142363A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628682A1 (fr) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues glucagon-like-peptide-2 (glp-2)
WO2021174048A1 (fr) 2020-02-28 2021-09-02 Kallyope, Inc. Agonistes de gpr40
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2024075135A1 (fr) * 2022-10-03 2024-04-11 Orbicular Pharmaceutical Technologies Private Limited Compositions injectables stables de peptide glp-2
US12297251B1 (en) 2017-06-16 2025-05-13 Zealand Pharma A/S Injection pen for subcutaneous administration of a peptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049314A2 (fr) * 1999-12-30 2001-07-12 Nps Allelix Corp. Formulations de glp-2
US7847061B2 (en) * 2004-11-01 2010-12-07 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US8163696B2 (en) * 2005-05-04 2012-04-24 Zealand Pharma A/S Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049314A2 (fr) * 1999-12-30 2001-07-12 Nps Allelix Corp. Formulations de glp-2
US7847061B2 (en) * 2004-11-01 2010-12-07 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
US8163696B2 (en) * 2005-05-04 2012-04-24 Zealand Pharma A/S Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUSAN LARUE ET AL.: "Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes", JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, vol. 9, no. 4, 2015, pages 815 - 821, XP055533878 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297251B1 (en) 2017-06-16 2025-05-13 Zealand Pharma A/S Injection pen for subcutaneous administration of a peptide
EP3628682A1 (fr) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations d'analogues glucagon-like-peptide-2 (glp-2)
WO2020065063A1 (fr) * 2018-09-28 2020-04-02 Zealand Pharma A/S Formulations d'analogues du peptide-2 de type glucagon (glp-2)
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2021174048A1 (fr) 2020-02-28 2021-09-02 Kallyope, Inc. Agonistes de gpr40
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
WO2024075135A1 (fr) * 2022-10-03 2024-04-11 Orbicular Pharmaceutical Technologies Private Limited Compositions injectables stables de peptide glp-2

Similar Documents

Publication Publication Date Title
WO2018142363A1 (fr) Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables
EP1498150B1 (fr) Dispositif pour l'administration d'une composition medicamenteuse solide
JP5683810B2 (ja) メトトレキセート濃厚溶液
JP6811270B2 (ja) ランレオチドの持続放出用の医薬組成物
US10342850B2 (en) Octreotide injection
JP2012096063A (ja) 医薬容器内の安定化した液体タンパク質の処方物
EP2662073B1 (fr) Injection d'octréotide
CN101095942A (zh) 一种包含稳定剂的Exendin注射剂药物配方
US20140287998A1 (en) Glucagon formulations
US20250032586A1 (en) Stable liquid compositions of glucagon
RU2777554C2 (ru) Инъекция октреотида
AU2023285400A1 (en) Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
HK1067870B (en) Device for delivery of solid drug compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18748644

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18748644

Country of ref document: EP

Kind code of ref document: A1